Holoclar for treating limbal stem cell deficiency after eye burns

Recommendation ID: TA467/1
Question: NICE agreed that further research was needed because there is currently no clinical- or cost-effectiveness evidence evaluating the use of Holoclar in both eyes in bilateral patients. The committee was aware of the ongoing HOLOCORE trial which is recruiting both unilateral and bilateral patients, but only evaluates the success of a second transplant in 1 eye rather than transplant success in both eyes.
Any explanatory notes (if applicable): N/A

Source guidance details

Comes from guidance: Holoclar for treating limbal stem cell deficiency after eye burns
Number: TA467
Date issued: August 2017

Is this a recommendation for the use of a technology only in the context of research?	No
Is it a recommendation that suggests collection of data or the establishment of a register?	No
Last Reviewed	31/08/2017